ANEB - NASDAQ
Anebulo Pharmaceuticals, Inc.
$1.72
-33%Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
At a Glance
Live SnapshotAnebulo Pharmaceuticals, Inc. Management Team
Mr. Daniel V. George
Acting Chief Financial Officer & Secretary
Compensation
$194,246
Mr. Richard Anthony Cunningham
Chief Executive Officer & Director
Compensation
$452,058
Dr. Kenneth C. Cundy Ph.D.
Chief Scientific Officer
Compensation
$492,756
Dr. Joseph F. Lawler M.D., Ph.D.
Founder & Chairman
Compensation
$11,000
Anebulo Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for ANEB.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
ANEB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | March 06, 2025 | March 06, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | October 30, 2023 | October 30, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 17, 2022 | October 17, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 22, 2021 | September 22, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.